-
03-29APOLLO Dream® Sirolimus Target Eluting Stent System Granted FDA Breakthrough Device DesignationShanghai, China – March 29, 2026 – Recently, The board of directors (the “Board”) of MicroPort NeuroScientific Corporation (the “Company”, 2172.HK, together with its subsidiaries, the “Group”) is pleased to announce that APOLLO Dream® Sirolimus Target Eluting Stent System (“APOLLO Dream®”) has been granted the Breakthrough Device Designation by the U.S. Food and Drug Administration (“FDA”).
-
10-22MicroPort NeuroScientific Receives Approval for Its NUMEN™ Silk in the USAWashington, USA, October 21, 2024 — On September 30, MicroPort NeuroTech (Shanghai) Co., Ltd., the subsidiary of MicroPort NeuroScientific received US FDA clearance for NUMEN™ Silk Coil Embolization System (NUMEN™ Silk), marking its second international market clearance following its initial clearance in the US.
-
09-06Announcement:MicroPort NeuroTech Officially Changes Its Name to MicroPort NeuroScientificWe are pleased to announce that our company has officially been renamed to MicroPort NeuroScientific Corporation.


" are registered trademarks of Shanghai MicroPort Medical (Group) Co., Ltd . They have been authorized to be used by MicroPort NeuroScientific and no other party shall use such trademarks without prior written permission thereof.